Publication date: Feb 11, 2025
The population-level impact of newer glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatments on patients with type 2 diabetes remains unclear. Therefore, this study investigated the association of newer GLP-1 RAs with population-level diabetes-related outcomes in US adults with type 2 diabetes. This was a noninterventional, retrospective analysis of administrative insurance claims data obtained from Optum’s de-identified Clinformatics(R) Data Mart Database between January 2004 and December 2022. Individual patient data were aggregated into monthly time series at the population level. Associations between the proportion of patients on newer GLP-1 RAs of interest (dulaglutide, once-weekly or oral semaglutide, and tirzepatide) and average hemoglobin A1c (HbA1c), HbA1c
| Concepts | Keywords |
|---|---|
| Adults | glycemic control |
| Diabetes | interrupted time series |
| Hemoglobin | time series analysis |
| Therapy | type 2 diabetes |
| Weekly |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Rasagiline |
| disease | MESH | Type 2 Diabetes |
| drug | DRUGBANK | Dulaglutide |
| drug | DRUGBANK | Semaglutide |